ANTI-ISCHEMIC AND ANTIOXIDANT ACTIVITY OF MELDONIUM IN IHD PATIENTS WITH STABLE ANGINA

Abstract

(IHD), stable angina of effort of functional class II (43 persons) – III (39 persons) (53.3±7.5 y.o., men - 71, women - 11), with concomitant arterial hypertension – in 21 patient. All patients received traditional anti-anginal disaggregation and hypolipidemic therapy. The therapy of patients of Group 1 was supplemented by meldonium (Mildronate®) at a dosage of 750 mg per day for 2 months. Patients of Group 2 continued to receive traditional therapy. After the period of wash-out (3 months) rotation of patients was done: meldonium was indicated to 750 mg/day for 2 months to a group of patients that previously didn’t receive meldonium previously.Materials and methods. Evaluation of physical tolerance by the cycle ergometer test; activity of free radical processes in the blood by the level of lipoperoxides degradation in blood – diene conjugate (DC), malondialdehyde (MDA). Results. Meldonium inclusion in the complex therapy was accompanied by increase of physical tolerance, reduction of DC and MDA levels in the blood, reduction of the frequency of angina attack and demand in sublingual nitrates. Conclusion. Application of Mildronate® in a composition of complex therapy of patients with stable angina allows increasing effectiveness of traditional anti-angina therapy.

Keywords

• ischemic heart diseases
• cytoprotectors
• free radical oxidation
• lipoproteids
• physical tolerance
• meldonium